Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study

The Texas Hepatocellular Carcinoma Consortium cohort study investigates risk factors of hepatocellular carcinoma (HCC) and biomarkers for early HCC detection in patients with liver cirrhosis. Adult patients with liver cirrhosis are enrolled at 5 clinical centers from 3 cities in Texas, with a target...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of gastroenterology Vol. 114; no. 3; pp. 530 - 532
Main Authors: Feng, Ziding, Marrero, Jorge A., Khaderi, Saira, Singal, Amit G., Kanwal, Fasiha, Loo, Nicole, Beretta, Laura, Ning, Jing, El-Serag, Hashem B.
Format: Journal Article
Language:English
Published: United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.03.2019
Subjects:
Biomarkers
Biomarkers - metabolism
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - epidemiology
Carcinoma, Hepatocellular - metabolism
Cohort analysis
Cohort Studies
Data collection
Disease prevention
Early Detection of Cancer
Epidemiology
Germ-Line Mutation
Glycated Hemoglobin - metabolism
Hepatitis B
Hepatitis C
Hepatology
Humans
Hypotheses
Inflammation - metabolism
Liver cancer
Liver cirrhosis
Liver Cirrhosis - diagnostic imaging
Liver Cirrhosis - epidemiology
Liver Cirrhosis - metabolism
Liver diseases
Liver Neoplasms - diagnosis
Liver Neoplasms - epidemiology
Liver Neoplasms - metabolism
Metabolic syndrome
Metabolic Syndrome - epidemiology
Mortality
Obesity - epidemiology
Prospective Studies
Risk factors
Surveillance
Texas
Triglycerides - metabolism
Texas
United States > US
ISSN:0002-9270, 1572-0241, 1572-0241
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Texas Hepatocellular Carcinoma Consortium cohort study investigates risk factors of hepatocellular carcinoma (HCC) and biomarkers for early HCC detection in patients with liver cirrhosis. Adult patients with liver cirrhosis are enrolled at 5 clinical centers from 3 cities in Texas, with a target of 5,000 patients. Clinical history, risk factor questionnaires, liver imaging, laboratory data, and blood samples were collected at enrollment and at each 6-month follow-up visit. The primary outcome was the development of HCC. Biomarkers were tested in banked blood samples using prospective specimen collection, retrospective blinded evaluation design. We describe study design, eligibility criteria, recruitment, study cores, and sample size and analysis considerations.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Specific author contributions: All authors wrote the article.
ISSN:0002-9270
1572-0241
1572-0241
DOI:10.14309/ajg.0000000000000068